Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review. [PDF]
Al-Mashdali AF +3 more
europepmc +1 more source
Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study. [PDF]
Zhang J +9 more
europepmc +1 more source
PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia. [PDF]
Qi J +18 more
europepmc +1 more source
Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. [PDF]
Ma C, Lu Y, Li J, Liu W, Liu J.
europepmc +1 more source
Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell-surface CXCR4 as a synergistic target for combinatorial therapy. [PDF]
Mladonicka Pavlasova G +13 more
europepmc +1 more source
Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma. [PDF]
Yao Y +6 more
europepmc +1 more source
Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. [PDF]
Sharma P, Jiang H, Liu D.
europepmc +1 more source
Safety and Clinical Performance of Peripherics™ Paclitaxel-Coated Balloon Catheter in Below-the-Knee Arteries: A Multicenter Post-market Study. [PDF]
Sarda P +4 more
europepmc +1 more source
Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis. [PDF]
Chen Y +6 more
europepmc +1 more source
Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report. [PDF]
Shakarchi FF +5 more
europepmc +1 more source

